What is the recommended medical management for ureteric stones in women?

Medical Management of Ureteric Stones in Women

For women with ureteric stones, offer medical expulsive therapy with alpha-blockers (particularly for distal stones >5 mm) combined with adequate analgesia, while reserving observation with trial of passage for smaller stones (<6 mm) with well-controlled symptoms. 1

Initial Assessment and Pain Management

Acute Pain Control

• First-line: NSAIDs (diclofenac 50-100 mg rectally or 75 mg IM, ibuprofen, or metamizole) are superior to opioids for renal colic 2
• Second-line: Opioids (hydromorphine, pentazocine, or tramadol—avoid pethidine due to high vomiting rates) 2
• Contraindication: NSAIDs are contraindicated in pregnancy and should be used cautiously in patients with low GFR 2
• Combination therapy with diclofenac, paracetamol, and/or codeine provides adequate control in most cases 3

Stone Size-Based Management Strategy

Stones <6 mm (EAU) or <10 mm (AUA):

• Conservative observation is appropriate with mandatory follow-up 1
• Maximum duration: 4-6 weeks from initial presentation (AUA recommendation) 1
• Spontaneous passage expected in most cases <5 mm 3

Stones 5-10 mm:

• Medical expulsive therapy is indicated, particularly for distal ureteral stones 1
• Up to 50% may require intervention 3

Stones >10 mm:

• Unlikely to pass spontaneously—discuss with urology for surgical intervention 3
• Intervention should be considered for stones >7 mm (SIU/ICUD) 1

Medical Expulsive Therapy (MET)

Alpha-Blocker Therapy

The evidence strongly supports alpha-blockers as the preferred MET agents:

• Efficacy: 29% more patients pass stones with alpha-blockers versus controls (statistically significant) 4
• Primary agent: Tamsulosin is most commonly studied, though terazosin and doxazosin are equally effective 4
• Optimal indication: Distal ureteral stones >5 mm (EAU strong recommendation) 1
• AUA specification: Recommends MET for distal ureteral stones only 1
• Additional benefits: Reduces stone passage time and limits pain 4
• Post-SWL use: Consider alpha-blockers after shock wave lithotripsy to facilitate fragment passage 1

Novel Evidence on MET Rankings

Recent umbrella review evidence (2026) identifies the most effective MET combinations 5:

• Highest-ranked: Naftopidil plus corticosteroids (SUCRA 91.8-90.6% in high-moderate certainty evidence)
• Second-ranked: Silodosin (SUCRA 94.8-82.5% in moderate-low certainty evidence)

Calcium Channel Blockers

• Nifedipine shows marginal benefit (9% improvement, not statistically significant) 4
• Less effective than alpha-blockers for routine use 4

Corticosteroids

• Small additional benefit when combined with alpha-blockers 4
• Consider in combination therapy based on recent evidence 5

Monitoring and Follow-Up

Mandatory Surveillance Components

• Clinical monitoring: Detect complications (fever, worsening obstruction, intractable pain)
• Imaging follow-up: Verify stone migration or elimination 6
• Urine culture: Obtain before any intervention to exclude/treat UTI 7, 2

Indications for Urgent Intervention

Immediate decompression required for:

• Sepsis with obstructing stone (ureteral stent or percutaneous nephrostomy) 7, 2
• Anuria in obstructed kidney 2
• Intractable symptoms despite adequate analgesia 8

Procedure: Collect urine for antibiogram before and after decompression, administer antibiotics immediately, delay definitive stone treatment until sepsis resolves 2

Special Considerations for Women

Pregnancy-Specific Management

Observation is first-line for pregnant women with well-controlled symptoms (AUA Strong Recommendation, Grade B) 9:

• Spontaneous passage rates similar to non-pregnant patients 9
• Stone passage occurs in 40-60% of pregnant women (mean time 17-35 days) 8
• Coordinate all interventions with obstetrician (Clinical Principle) 9

If observation fails:

• Preferred: URS for definitive treatment (preferred timing: second trimester after fetal viability) 8, 9
• Alternative: Ureteral stent or nephrostomy tube with frequent exchanges (stones encrust rapidly in pregnancy) 9

Contraindications in pregnancy:

• NSAIDs (ketorolac and others) are contraindicated 9
• MET inadequately studied—counsel regarding off-label use 9
• Tamsulosin studies show no adverse maternal/fetal effects but no significant benefit for stone passage 8

Imaging Considerations

• First-line: Ultrasound (strongly recommended for pregnant women and children) 2
• Second-line: MRI for pregnant women 2
• Last resort: Low-dose CT only when absolutely necessary 2

Common Pitfalls to Avoid

1. Duration error: Don't extend conservative management beyond 4-6 weeks without urological consultation 1
2. Size misjudgment: Stones >10 mm rarely pass spontaneously—early urology referral prevents complications 3
3. Infection oversight: Always obtain urine culture before intervention; missing infected obstructed kidney can be catastrophic 7, 2
4. NSAID misuse: Avoid in pregnancy and severe renal impairment 2
5. MET overuse: Alpha-blockers most beneficial for distal stones >5 mm; limited benefit for proximal or very small stones 1
6. Pregnancy management: Don't withhold necessary intervention due to pregnancy—coordinate with obstetrics but don't delay medically necessary procedures 8, 9

Practical Algorithm

Step 1: Assess stone size and location via imaging (low-dose CT preferred, ultrasound if pregnant)

Step 2: Provide adequate analgesia (NSAIDs first-line unless contraindicated)

Step 3: Determine management pathway:

• <6 mm: Observation with follow-up (maximum 4-6 weeks)
• 5-10 mm distal: Alpha-blocker MET + observation
• >10 mm or proximal: Urology consultation for surgical planning

Step 4: Monitor for complications requiring urgent intervention (sepsis, anuria, intractable pain)

Step 5: If pregnant, default to observation unless symptoms uncontrolled, then coordinate with obstetrics for URS